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A B S T R A C T
Multiple sclerosis is the most common inﬂammatory demyelinating disease of the central nervous
system, caused by an autoimmune response against myelin that eventually leads to progressive
neurodegeneration and disability. Although the knowledge on its underlying neurobiological
mechanisms has considerably improved, there is a still unmet need for new treatment options,
especially for the progressive forms of the disease. Both preclinical and clinical data suggest that
cannabinoids, derived from the Cannabis sativa plant, may be used to control symptoms such as spasticity
and chronic pain, whereas only preclinical data indicate that these compounds and their endogenous
counterparts, i.e. the endocannabinoids, may also exert neuroprotective effects and slow down disease
progression. Here, we review the preclinical and clinical studies that could explain the therapeutic action
of cannabinoid-based medicines, as well as the medical potential of modulating endocannabinoid
signaling in multiple sclerosis, with a link to other neuroinﬂammatory disorders that share common
hallmarks and pathogenetic features.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Although the central nervous system (CNS) has been long
considered an immune-privileged site, mainly due to the presence
of the blood brain barrier (BBB), immune activities occur and are
sometimes ncesessary for neuronal function and host defence
(Banks, 2015). Any insult of the brain is associated with acute
inﬂammation, characterized by endothelial cell activation, tissue
oedema and release of inﬂammatory mediators that provide to
eliminate the insult and restore brain function. However, neuro-
inﬂammation is widely regarded as a chronic process that involves
both sustained activation of resident glial cells (microglia and
astroglia) and recurrent inﬁltration of peripheral leukocytes and
soluble inﬂammatory mediators. Microglial cells, either derived
from mesenchymal monocyte precursors of the mesoderm or from
non-hematopoietic microglial precursors in the yolk sac, both
entering the brain during embryonic and fetal stages, are the
immune sentinels of the CNS. Microglial cells are extremely
heterogeneous, because they can exist in many different forms and
activation states, from neuro-protective to neuro-destructive
(Nayak et al., 2014). Microglial cells are critical for the development
and surveillance of the CNS, shaping the immune phenotype of the
brain and critically modulating neuroinﬂammation (Mosser et al.,
2017). Astrocytes are by far the most abundant cells in the CNS,
where they regulate virtually every physiological process, from
physically forming the BBB and giving nutritional support to
sustaining neurotransmitters turnover, synaptic plasticity and
immune functions. Indeed, immune activation of astrocytes in
response to signals released by injured neurons or activated
microglia leads to the so-called astrogliosis, a hallmark of
neuroinﬂammation, which leads to glial scars that prevent axonal
regeneration (Jensen et al., 2013). During neuroinﬂammation also
immune cells of both innate (monocytes/macrophages and
dendritic cells) and adaptive (T and B lymphocytes) immunity
are persistently recruited to the brain, and release inﬂammatory
cytokines and chemokines that exacerbate neuroinﬂammation
(Schwartz and Baruch, 2014). As a matter of fact, neuroinﬂamma-
tion often may lead to neurodegeneration, axonal loss and synaptic
dysfunction, and thus it is typically associated with several
neurological disorders, of which multiple sclerosis (MS) is the
prototypical example. MS is a progressive, chronic neurodegener-
ative disease, which affects approximately 2.3 million people
worldwide (Browne et al., 2014). It is the most common
neurological disorder in young adults, and is regarded as an
autoimmune disease in which inﬂammation leads to demyelin-
ation of the axons in the CNS. Although the aetiology of MS is still
unknown, it is almost unanimously believed that both genetic and
environmental components play a central role in disease onset and
development (Haﬂer et al., 2007; Huynh and Casaccia, 2013). The
MS prevalence ratio of women to men (2.3–3.5:1) has increased
markedly during the last decades and this rapid increase probably
reﬂects a differential gender response to unidentiﬁed changes in
environment or nutrition (Harbo et al., 2013). MS is characterized
by a series of episodic acute attacks (referred to as relapses) and
remissions, but it gradually leads to progressive neurodegenera-
tion and deterioration of neurologic function without any further
remission. Although the different clinical courses of MS (also called
“types” or “phenotypes”) were deﬁned in 1996, the InternationalPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dAdvisory Commette on Clinical Trials of MS, based on advances in
the understanding of the disease process in MS and MRI
technology, classiﬁed MS into only four independent subtypes:
(i) relapsing-remitting (RR), deﬁned by unpredictable relapses
with full recovery or with sequelae; (ii) primary progressive (PP),
which progresses continuously from the onset without attacks;
(iii) secondary progressive (SP), which follows initial RR and then
progresses with decline without remissions; and (iv) progressive
relapsing (PR), characterized by a steady decline onset with super-
imposed attacks (Fig. 1). The RR-MS is the most prevalent form and
accounts for approximately 85% of all cases (Compston and Coles,
2008; Lublin et al., 2014). However, the Committee also recognized
the clinically isolated syndrome (CIS) as a ﬁrst episode of
neurologic symptoms caused by inﬂammation and demyelination
that must last at least 214 h and that is characteristic of MS even
though does not yet meet the criteria for its diagnosis because
patients with CIS might also not end up developing MS (Lublin
et al., 2014). MS pathogenesis and pathophysiology have been
extensively studied, especially in the experimental autoimmune
encephalomyelitis (EAE) mouse model, and are thought to involve
initially the disruption of the immune system and of central
myelin-producing cells. In the course of MS, damage to the BBB and
over-activation of brain microglia lead to a substantial inﬁltration
of autoreactive lymphocytes, causing oligodendrocyte death and
axonal damage and ultimately resulting in demyelination, synaptic
alteration and neuronal loss (Compston and Coles, 2008; Dutta and
Trapp, 2011; Calabrese et al., 2015; Mahad et al., 2015) (Fig. 2).
Though the immune-mediated neuroinﬂammation hypothesis
has dominated MS research for over 50 years, recent evidence
seems to point to a neurodegenerative and microglia-centered
process, according to which MS is primarily a neurodegenerative
disease that starts in the brain, and then develops because of
inﬂammation (Kassmann et al., 2007; Lassmann et al., 2012). This
has led to the current “inside-out” and “outside-in” models of MS
immunopathogenesis, whereby in the ﬁrst model the immune
response that destroys myelin and leads to BBB breakdown is
driven by a dysfunction of brain cells, whereas in the second model
a dysfunction residing in the periphery leads to BBB damage,
myelin disruption and axonal death (Tsunoda and Fujinami, 2002;
Stys et al., 2012).
The immune-mediated attacks are mainly driven by cells of
adaptive immunity, namely myelin-speciﬁc and self-reactive CD8
amd CD4 T-cells (T-helper 1 and T-helper 17), with a key
contribution of B-cells that produce high levels of autoantibodies
and that have been recently shown to contribute to neuro-
degeneration and cortical demyelination, especially for meningeal
ectopic B cell follicles (Fraussen et al., 2016). During these attacks,
the myelin sheath is damaged, thus impairing axonal conduction
and the correct communication between different parts of the
nervous system (Compston and Coles, 2008; Gandhi et al., 2010;
Mahad et al., 2015). These processes are sustained by a subsequent
recruitment of cells of the innate immunity from the periphery
that further amplify the activation of pathogenic T-cells and the
destruction of neurons and oligodendrocytes. In addition, there is a
permanent activation of resident microglia and astrocytes that
further potentiate the neuroinﬂammatory response by producing
proinﬂammatory mediators (Gandhi et al., 2010; Chiurchiù, 2014)
(Fig. 2). Oligodendrocytes are responsible for myelin productionid system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Fig. 2. Immunopathogenesis of MS. Injury to blood-brain barrier (BBB) and/or hyperactivation of brain microglial cells lead to a massive inﬁltration in the central nervous
system of autoreactive T cells (CD8 and CD4 T-helper cells), B cells and antigen-presenting cells (APCs), including monocytes/macrophages. In the brain, Tcells and monocytes/
macrophages release cytokines and chemokines that damage the oligodendroglial cells, and hence the myelin sheath. Concomitantly, B cells (plasma cells) produce myelin-
speciﬁc antibodies, which form membrane-attack complexes that further damage myelin sheath. These processes also lead to an over-activation of microglia and astrocytes,
which further potentiate the inﬂammatory response.
Fig. 1. The immunological basis of the different clinical forms of MS.
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especially in the early phases of the disease. Remyelination is one
of the reasons why symptoms tend to decrease or disappear
temporarily in RR-MS (Peferoen et al., 2014). However, oligoden-
drocytes are unable to completely rebuild the myelin sheath and
repeated attacks lead to less and less effective remyelination, until
scar-like plaques (scleroses) build up around the damaged axons
with subsequent axonal loss (Cambron et al., 2012). These scars,
usually more than 10 as visualized by magnetic resonance imaging
(MRI), determine a wide range of symptoms, including physical
disability, fatigue, and cognitive impairment (Polman et al., 2011).
Approximately 10 years after disease onset, frequent relapses and
remissions give pace to a progressive clinical aggravation. Such an
evolution from relapsing-remitting to progressive forms of MS
certainly involves the loss of oligodendroglia and neurons most
likely due to several concurrent events, including (i) disruption of
peripheral immune tolerance and a subsequent shift to innate
immunity (plaques contain more monocyte/macrophages and
dendritic cells and fewer T cells in chronic disease), (ii) reduced
neurotrophic abilities of astrocytes on neurons, (iii) increased loss
of oligodendrocyte precursor cells and (iv) toxic effects on axons
(Gandhi et al., 2010; Reynolds et al., 2011) (Fig. 1).
At any rate, all these noxious effects appear to be causing the
widespread, cortical and subcortical grey matter atrophy since the
early stages of the disease as observed by MRI and analysis of post-
mortem MS patient samples (Mandolesi et al., 2015; Musella et al.,
2016). Neurodegeneration leads to permanent and increasing
disability, with spasticity and pain as important hallmarks of the
disease.
Current therapies for MS focus on the prevention of relapses in
the early stage, mainly stopping the immune attacks with drugs
that directly inhibit cell activation and the release of inﬂammatory
mediators, or that prevent leukocyte recruitment into the CNS.
However, almost no drugs that prevent or slow down theTable 1
Major (endo)cannabinoids, and main metabolic enzymes of eCBs with a 
Name (abbreviation) 
D9-Tetrahydrocannabinol (THC)
Cannabidiol (CBD)
N-Arachidonoylethanolamine (Anandamide, AEA)
2-Arachidonoylglycerol (2-AG)
Biosynthetic enzyme of AEA 
N-acylphosphatidyl ethanolamines (NAPE)-speciﬁc phospholipase D (N
Biosynthetic enzymes of 2-AG 
Diacylglycerol lipase a (DAGLa) 
Diacylglycerol lipase b (DAGLb) 
Degrading enzyme of AEA 
Fatty acid amide hydrolase (FAAH) 
Degrading enzyme of 2-AG 
Monoacylglycerol lipase (MAGL) 
Please cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://doccurrence of neurodegeneration and disease progression are
yet available, with the exception of the very recently approved
humanized monoclonal antibody Ocrelizumab (Ocrevuz1) for
primary progressive MS patients (Montalban et al., 2017). Approval
of Nabiximol (Sativex1, a 1:1 mixture of D9-tetrahydrocannabinol
(THC) and cannabidiol (CBD), both isolated from Cannabis sativa) to
treat MS-induced spasticity was recently obtained in several
countries (Zettl et al., 2016; Maccarrone et al., 2017). Since
preclinical data show that cannabinoids also exert anti-inﬂamma-
tory properties and neuroprotective effects (Chiurchiù et al.,
2015a), it is hypothesized that these substances may limit
progressive neurodegeneration in MS (Pryce et al., 2003; Jackson
et al., 2005; Witting et al., 2006). Here, we will review the role of
cannabinoids and their endogenous counterparts (i.e., the endo-
cannabinoids, eCBs) in MS, their mode of action and preclinical and
clinical signiﬁcance, as well as how their pharmacological
modulation could be useful to treat other neuroinﬂammatory
diseases.
2. A glimpse to the eCB system
2.1. Cannabinoids and cannabinoid receptors
For over 5000 years, Cannabis (Cannabis sativa) has long been
used for recreational and medicinal purposes for more than 5000
years. Cannabis extracts like marijuana contain more than 500
natural compounds, out of which over 110 belong to cannabinoids
(Maccarrone et al., 2017). Although the ﬁrst isolated plant-derived
cannabinoids were cannabinol and cannabidiol (CBD), the
identiﬁcation of the major psychoactive constituent THC was
achieved later on (Table 1) (Adams, 1942; Gaoni and Mechoulam,
1964), establishing the current ﬁeld of cannabinoid research.
Several cannabinoids have distinct biological activity, yet THC and
CBD were particularly studied due to their broad spectrum ofrole in neuroinﬂammation.
Chemical structure
Intracellular localization
APE-PLD) Membrane-associated
Intracellular localization
Membrane-associated
Membrane-associated
Intracellular localization
Membrane-associated (mainly ER)
Intracellular localization
Membrane-associated and cytosolic
id system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
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stereoselectively acts in the CNS (Mechoulam et al., 1988) by
binding to a speciﬁc target identiﬁed as the type-1 cannabinoid
receptor (CB1) (Devane et al., 1988). Few years later a type-2
cannabinoid receptor (CB2) was discovered in peripheral B- and T-
lymphocytes (Munro et al., 1993). THC binds to both CB1 and CB2
with high afﬁnity (Huffman, 2000; Mahadevan et al., 2000),
whereas CBD, a non-psychoactive component, shows little afﬁnity
for both receptors (Mechoulam et al., 2007). Upon activation both
receptors inhibit the formation of the second messenger cAMP, and
modulate other signal transduction pathways such as extracellular
regulated kinases, b-arrestin, and ion channels. There is a debate
on the expression levels of CB1 and CB2 in different cell types and
its subcellular localisation, but there is a general consensus that
CB1 is widely expressed within the CNS in cortical neurons and
interneurons, astrocytes, oligodendrocytes and oligodendrocyte
precursor cells, as well as in several leukocytes inﬁltrating the
brain (Navarrete and Araque, 2010; Galve-Roperh et al., 2013). CB1
regulates cognitive, memory and motor functions as well as
analgesia and synaptic plasticity. On the contrary, the expression of
CB2 in cells of the CNS is more controversial, inasmuch as its
presence for a long time was exclusively associated to microglia,
but more recently it was also documented in brainstem neurons
and astrocytes upon cellular activation by an insult or inﬂamma-
tion (Van Sickle et al., 2005; Onaivi et al., 2006; Atwood and
Mackie, 2010; et al., 2015a, 2015b; et al., 2015a, 2015b).
Furthermore, a substantial proportion of CB1 in the brain is
intracellular, being found in vesicles (Leterrier et al., 2004),
mitochondria (Bénard et al., 2012) or lysosomes (Rozenfeld and
Devi, 2008). Interestingly, the human brain has more CB1 than any
other G protein-coupled receptor.
2.2. Endogenous ligands of cannabinoid receptors and their metabolic
routes
Unsurprisingly, in view of the lipophilic nature of THC, the
endogenous ligands of CB receptors, i.e. the endocannabinoids
(eCBs), are derivatives of the lipid arachidonic acid (AA). The most
important eCBs are N-arachidonoylethanolamine (anandamide,
AEA) and 2-arachidonoylglycerol (2-AG) (Table 1). These two
endogenous ligands of CB1 and CB2 are the best-studied members
of an ever-growing family of compounds (Maccarrone et al., 2014;
Mechoulam et al., 2014) that include N-acylethanolamines, 2-
monoacylglycerols, and now also peptidic eCBs (pepcans) (Bauer
et al., 2012). This large family also includes the recently discovered
ethanolamines of v-3 (n-3) fatty acid, namely N-eicosapentae-
noylethanolamine (EPEA) and N-docosahexaenoyl-ethanolamine
(DHEA) (Artmann et al., 2008; Lucanic et al., 2011). EPEA and DHEA
act indeed as CB1/CB2 agonists (Brown et al., 2010), but their
function still needs to be clariﬁed. There are additional compounds
that do not bind to CB1 and/or CB2, but are processed by the same
synthesizing and degrading enzymes as authentic eCBs; these so-
called “eCB-like” substances include N-palmitoylethanolamine
(PEA) and N-oleoylethanolamine (OEA) (Ueda et al., 2013).
Both AEA and 2-AG are often found together, but their
individual levels vary between species, tissues, developmental
stages and pathophysiological conditions. Within the CNS and
amidst glial and neuronal cells, AEA and 2-AG act as retrograde
messengers, i.e. they are released from somata and/or dendrites of
neurons, and then act on afferent axon terminals or nearby
astroglial processes to inhibit neurotransmitter release (Ohno-
Shosaku et al., 2001; Wilson and Nicoll, 2001). Depending on
neuron type glutamatergic or g-aminobutyric acid (GABAergic),
activation of CB1 may results in inhibition or activation of the
neuronal circuit. Unlike other neurotransmitters, eCBs are not
stored in vesicles, but are produced “on demand” (i.e., when andPlease cite this article in press as: V. Chiurchiù, et al., The endocannabinoi
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dwhere needed) upon different biological stimuli, to act paracrinally
or autocrinally. At least ﬁve different pathways can generate AEA
(Di Marzo et al., 1994; Leung et al., 2006; Liu et al., 2006), the most
studied being the release of AEA from membrane precursors via N-
acylphosphatidyl-ethanolamine (NAPE)-speciﬁc phospholipase D
(NAPE-PLD) (Okamoto et al., 2004). Cleavage of AEA into AA and
ethanolamine is mainly operated by fatty acid amide hydrolase
(FAAH) (Cravatt et al., 1996). On the other hand, 2-AG is formed by
the action of two diacylglycerol lipases, DAGLa and DAGLb
(Bisogno et al., 2003), and is primarily degraded into AA and
glycerol by monoacylglycerol lipase (MAGL) (Dinh et al., 2002) and
to a lesser extent by a/b-hydrolase domain (ABHD) 6 and ABHD12
(Blankman et al., 2007). Furthermore, AEA and 2-AG can also be
metabolized by cyclooxygenase-2 (COX-2), several lipoxygenase
isozymes and by cytochrome P450, generating oxidized com-
pounds like prostaglandin-ethanolamides and glyceryl esters,
hydroxy-anandamides and hydroxyeicosatetraenoyl-glycerols, re-
spectively. All these substances can bind to CB1 and CB2, and are
endowed with distinct, yet unclear, biological activities (van der
Stelt et al., 2002; Rouzer and Marnett, 2011). All eCBs can also be
inactivated through their uptake by a purported “endocannabinoid
membrane transporter” (EMT), whose molecular identiy has yet to
be identiﬁed but whose presence has been suggested by several
reports as well as by its in vitro and in vivo pharmacological
targeting (Chicca et al., 2017). Overall, the activity and function of
eCBs is controlled by their endogenous tone, which depends on a
ﬁnely regulated balance between biosynthetic and degradative
pathways. At variance with this picture more recently it has been
demonstrated that AEA can be stored in lipid droplets (adipo-
somes) and bound to intracellular transporters (Maccarrone et al.,
2010). These additional players seem to be relevant, because
neurophysiological actions of eCBs depend on the speciﬁc location
of the proteins that synthesize, transport, bind and degrade them,
altogether called “eCB system” (Maccarrone et al., 2014, 2015). The
complexity and distinct distribution of eCB system components in
pre- and post-synaptic neurons, as well as in microglia and
astrocytes, is schematically depicted in Fig. 3.
2.3. Other receptors
In addition to CB1 and CB2, cannabinoids and eCBs can exert
their effects engaging other non-CB receptors, including the
transient receptor potential vanilloid 1 (TRPV1) channel, expressed
mainly in peripheral tissues, including peripheral sensory neurons,
epithelial and endothelial cells as well as immune cells (Xia et al.,
2011). Other targets are peroxisome proliferator-activated recep-
tors (PPAR) a and g (Pistis and Melis, 2010) that belong to a family
of nuclear receptors whose role is mainly to control lipid
metabolism; and orphan G protein-coupled receptor GPR55
(Moriconi et al., 2010). The existence of such supplementary
molecular targets support the view that an extension of the term
“cannabinoid receptor” should really be encouraged. The multi-
plicity of cannabinoids and eCBs at interacting with many other
non-CB receptors and the evidence that cannabinoid receptors are
able to bind to other ligands other than cannabinoids and eCBs
endorse such view.
3. Therapeutic exploitation of the endocannabinoid system in
multiple sclerosis
3.1. Preclinical ex vivo and in vivo studies of eCB signaling in MS
To establish whether a drug is ready for clinical trials (the so-
called move from bench to bedside) involves extensive preclinical
studies that yield preliminary efﬁcacy, pharmacokinetic, safety and
toxicological information. The starting point of such studies isd system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Fig. 3. A modern view of the eCB system in the CNS. eCB signaling is orchestrated by target receptors (CB1, CB2, GPR55, TRPV1 and PPARs), biosynthetic (NAPE-PLD and DAGL)
and degradative (FAAH, MAGL, ABHD6 and ABHD12) enzymes, transmembrane transport mechanisms (like the putative EMT), intracellular trafﬁcking by AITs like fatty acid
binding proteins, heat shock protein 70, and FAAH-like AEA transporter, as well as by storage organelles (adiposomes or lipid droplets). Altogether, these proteins regulate the
endogenous tone of eCBs, and hence their biological activity. For some of the elements of the eCB system a distinct distribution, both intracellularly and among pre- and post-
synaptic neurons, microglia and astrocytes, has been documented. It should be noted that, unlike other eCB-binding receptors, CB1 appears to be located in cholesterol-
enriched membrane microdomains termed LRs, and that CB2 is expressed in neurons mainly upon brain injury. Moreover, the role in neuroinﬂammatory diseases of eCB
system elements shown here but not listed in Table 1 remains to be elucidated.
Abbreviations: ABHD6/12, a-b-hydrolase domain 6/12; AITs, AEA intracellular transporters; CB1/CB2, G-protein coupled type-1 and type-2 cannabinoid receptors; DAGL,
diacylglycerol lipase a/b; eCBs, endocannabinoids; EMT, putative endocannabinoid transmembrane transporter; FAAH, fatty acid amide hydrolase; GPR55, G-protein coupled
receptor 55; LRs, lipid rafts; MAGL, monoacylglycerol lipase; NAPE-PLD, N-acylphosphatidylethanolamine-speciﬁc phospholipase D; PPARs, peroxisome proliferator-
activated nuclear receptors; TRPV1, transient receptor potential vanilloid 1 channels.
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expression of a certain molecular target (often a protein) in
disease models, or in affected patients, either in vitro (experiment
and analysis performed outside a living organism) or ex vivo
(experiment performed inside and analysis outside a living
organism). In this line, accumulated ex vivo evidence showed a
wide alteration of CB1 and CB2 expression in several experimental
models of MS and in patients affected by different clinical forms of
the disease (Benito et al., 2003, 2007; Cabranes et al., 2005; Loría
et al., 2008; Jean-Gilles et al., 2009; Chiurchiù et al., 2013; Sánchez
López et al., 2015; Maccarrone et al., 2017). This observation
strongly suggests a functional role for cannabinoid receptors in MS
pathology, and has stimulated preclinical studies directed at
modulating their activity by in vivo administration of plant
cannabinoids, synthetic agonists or antagonists (Table 2). The ﬁrst
such preclinical study demonstrated an amelioration of both
tremor and spasticity in mice suffering from chronic relapsing EAE
upon in vivo treatment with THC, methanandamide (a stable and
non-hydrolizable AEA anolog), and synthetic CB1 or CB2 agonists
(Baker et al., 2000). Selective antagonists of CB1 or CB2 inhibited
these effects, indicating that the eCB system may participate in
the control of MS. In addition to symptom management,
cannabinoids also conferred neuroprotection via CB1, slowing
down the neurodegenerative process that eventually leads to
chronic disability (Pryce et al., 2003). Furthermore, they caused
immunosuppression-mediated amelioration of symptom progres-
sion and promoted remyelination also in a viral model of MS
(Croxford and Miller, 2003; Arévalo-Martín et al., 2003). Such CBPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dreceptor-mediated neuroprotection and interference with MS
progression were paralleled by downregulation of adhesion
molecules and subsequent inhibition of T lymphocyte inﬁltration
and microglial responses (Mestre et al., 2009; Zhang et al., 2009;
Kozela et al., 2011), as well as by restoration of self-tolerance to
myelin antigen (Arévalo-Martín et al., 2012). Selective activation
of CB2 in autoreactive T-cells was crucial to control inﬂammation
in EAE (Maresz et al., 2007) by reducing highly pathogenic T-
helper 17 differentiation and immune cell accumulation in the
CNS, including activated macrophages/microglia (Kong et al.,
2014). In line, selective activation of CB2 on T lymphocytes
isolated from MS patients inhibited cell proliferation and immune
responses without inducing cell death (Malﬁtano et al., 2013). The
involvement of CB receptors was conﬁrmed not only by
pharmacological modulation of their activity but also by their
genetic deletion. Accordingly, mice whose CB1 was genetically
ablated poorly tolerated inﬂammatory and excitotoxic insults and
developed substantial neurodegeneration (Pryce et al., 2003;
Rossi et al., 2011a; Musella et al., 2014). Similarly, speciﬁc deletion
of CB2 on encephalitogenic T cells increased proliferation, reduced
T-cell apoptosis, elevated production of proinﬂammatory cyto-
kines and worsened the symptoms. This scenario suggested that
activation of CB2 on T-cells by eCBs was sufﬁcient to control
autoimmune inﬂammation, and possibly to slow down progres-
sion of the disease (Maresz et al., 2007). These studies indicate the
involvement of both CB1 and CB2 in the therapeutic efﬁcacy of the
eCB system modulation. They also suggest a differential role
played by these two receptor sub-types, whereby control ofid system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Table 2
Alterations of distinct elements of the eCB system, and their role in inﬂammation and neurodegeneration in MS.
ECS
element
Model Sample Variation Effects Reference
AEA Chronic EAE Brain, spinal cord " Early inhibition of spasticity Baker et al. (2001)
Lewis EAE rats Brain # Worsening of disease development and
neurological impairment
Cabranes et al. (2005)
RR-MS Autopsied brain " Microglia-induced neuroprotection Eljaschewitsch et al. (2006)
EAE and RR-MS
patients
Brain, CSF, plasma, T cells " Neuroprotection Centonze et al. (2007a)
RR-MS, SP-MS CSF # – Di Filippo et al. (2008)
RR-MS, PP-MP,
SP-MS
Plasma " Disease progression Jean-Gilles et al. (2009)
RR-MS T cells, B cells, NK cells " – Sánchez López et al. (2015)
NAPE-PLD/
FAAH
EAE and RR-MS
patients
Brain, CSF, plasma, T cells " NAPE-PLD and
#FAAH
Neuroprotection Centonze et al. (2007a)
SP-MS Plasma #FAAH Disease progression Jean-Gilles et al. (2009)
RR-MS mDC and pDC #FAAH in mDC
and " in pDC
Lack of immunoregulation Chiurchiù et al. (2013)
RR-MS T cells, B cells, NK cells  ! – Sánchez López et al. (2015)
2-AG Chronic EAE Brain, spinal cord " Late inhibition of spasticity Baker et al. (2001)
Lewis EAE rats Brain # Worsening of disease development
and neurological impairment
Cabranes et al. (2005)
RR-MS patients CSF  ! – Centonze et al. (2007a)
RR-MS, SP-MS CSF # – Di Filippo et al. (2008)
TMEV-IDD Spinal cord " – Loría et al. (2008)
RR-MS T cells, B cells, NK cells Increased in NK
cells
– Sánchez López et al. (2015)
DAGL/
MAGL
EAE – – Inhibition of MAGL ameliorates
EAE progression
Hernández-Torres et al.
(2014)
CB1 Lewis EAE rats Brain # Worsening of disease development and
neurological impairment
Cabranes et al. (2005)
P-MS Plasma " Disease progression Jean-Gilles et al. (2009)
MS plaques Neurons, oligodendrocytes,
inﬁltrated T cells
" Disease progression Benito et al. (2007)
RR-MS T cells, B cells, NK cells "in T cells – Sánchez López et al. (2015)
CB2 TMEV-IDD Spinal cord " – Loría et al. (2008)
P-MS Plasma " Disease progression Jean-Gilles et al. (2009)
MS plaques Inﬁltrated T cells, astrocytes,
microglia
" Disease progression Benito et al. (2007)
RR-MS mDC and pDC "in mDC and
 !in pDC
Lack of immunoregulation Chiurchiù et al. (2013)
RR-MS T cells, B cells, NK cells Increased in
B cells
– Sánchez López et al. (2015)
CSF, cerebrospinal ﬂuid; EAE, experimental autoimmune encephalomyelitis; mDC, myeloid dendritic cells; RR, relapsing-remitting; P, progressive; pDC, plasmacytoid
dendritic cells; PP, primary progressive; SP, secondary progressive; TMEV-IDD, Theiler's murine encephalomyelitis virus-induced demyelinating disease. ", increase; #,
decrease; !, unchanged.
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overactive and exacerbated immune responses by (Pryce and
Baker, 2007; Palazuelos et al., 2008).
Much alike CB1 and CB2, metabolic enzymes of eCBs have been
found to be signiﬁcantly altered in both MS patients (Baker et al.,
2001; Cabranes et al., 2005; Benito et al., 2007; Centonze et al.,
2007a,b; Di Filippo et al., 2008; Jean-Gilles et al., 2009; Chiurchiù
et al., 2013; Sánchez López et al., 2015) and animal models of the
disease (Baker et al., 2001; Pryce et al., 2003; Witting et al., 2006;
Loría et al., 2008) (Table 2). These alterations of eCBs and of their
metabolism are still somewhat controversial, most likely because
of different experimental models used and variations in MS
patients’ recruitment and stratiﬁcation. Despite these controver-
sies, the anti-inﬂammatory and neuroprotective role of eCBs is
widely documented in both in vivo and ex vivo experiments on cells
obtained from either experimental models of MS or from authentic
MS patients (Witting et al., 2006; Mestre et al., 2005; Ortega-
Gutiérrez et al., 2005; Loría et al., 2010). Exogenous administration
of eCBs improved control of spasticity (Baker et al., 2000, 2001) and
protected neurons from inﬂammatory damage possibly by
engaging CB receptors on microglial cells (Eljaschewitsch et al.,
2006). Additionally, inhibition of endogenous AEA uptake and of its
degradation by FAAH was shown to ameliorate motor symptoms
(Baker et al., 2001; de Lago et al., 2004). This improvement wasPlease cite this article in press as: V. Chiurchiù, et al., The endocannabinoi
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dassociated with reduced inﬂammatory responses in the spinal cord
(Mestre et al., 2005) along with downregulation of macrophage
and microglial function (Mestre et al., 2005; Ortega-Gutiérrez
et al., 2005). In a virus-induced model of MS, AEA inhibited
microglial activation by lowering interleukin (IL)-23 and IL-12
release (Correa et al., 2011), as well as IL-1b and IL-6 (Hernangó-
mez et al., 2012). Inhibition of the last two pro-inﬂammatory
cytokines was mediated by a mechanism involving CB2 receptor-
mediated recovery of the interaction between CD200 (expressed in
neurons) and its receptor (expressed in macrophages/microglia).
Such an interaction appears to be disrupted in MS, thus exposing
neurons to macrophages/microglia-induced neurotoxicity and
cytokine release (Hernangómez et al., 2014). Recently, we have
demonstrated that the anti-inﬂammatory role of AEA in MS is cell
type-speciﬁc, since it inhibits cytokine production only in myeloid
dendritic cells (Chiurchiù et al., 2013). Instead, plasmacytoid
dendritic cells were unresponsive to AEA due to a signiﬁcant
upregulation of FAAH compared to healthy subjects (Chiurchiù
et al., 2013). Interestingly, chronic and long-term inhibition of
FAAH (via genetic ablation) resulted in clinical remission and
improved long-term outcome in EAE mice (Webb et al., 2008).
Further, the acute phase of MS was ameliorated by increased levels
of 2-AG that inhibited spasticity when given at 10 mg/kg (Baker
et al., 2001) and caused a delayed onset in acute and chronic EAEd system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
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effect was probably mediated by recruitment of anti-inﬂammatory
macrophages (Lourbopoulos et al., 2011).
Based on these eCB-mediated neuroprotective actions, selective
inhibitors of FAAH and MAGL, that degrade AEA and 2-AG
respectively, were used in vivo to increase the tone and thus
potentiate the effects of these eCBs. The blockade of AEA
degradation by several potent and selective FAAH inhibitors was
in fact able to control spasticity in Biozzi ABH mice (Pryce et al.,
2013), another mouse model of MS that reproduces both relapsing-
remitting course and secondary progressive neurological aspects
(Amor et al., 2005). Likewise, MAGL inhibitors controlled spasticity
(Pryce et al., 2013), preserved myelin integrity by suppressing
oligodendrocyte excitotoxicity and microglial activation (Bernal-
Chico et al., 2015), and slowed the clinical progression of EAE
(Hernández-Torres et al., 2014; Brindisi et al., 2016).
Several preclinical studies have recently shown that eCB
signalling controls synaptopathy, another hallmark of MS and
neuroinﬂammation. Loss of homeostatic control of neurotrans-
mission and subsequent synapse dysfunction is deeply affected by
inﬂammation. Excitatory (glutamatergic) and inhibitory (GABAer-
gic) synapses are privileged sites of action for eCBs and act in
concert with proinﬂammatory cytokines (in particular IL-1b and
tumour necrosis factor-a, TNF-a). Neuroinﬂammation unbalances
synaptic transmission towards excitation, that ultimately results in
excitotoxic neurodegeneration (Mandolesi et al., 2015), and
activation of CB1 dampens the enhancing effects of TNF-a on
postsynaptic glutamate receptor expression and function (Rossi
et al., 2011b), and reduces the frequency of spontaneous
glutamate-mediated synaptic currents in striatal neurons, thus
contrasting the effects of IL-1b on glutamate release from
presynaptic nerve terminals (Musella et al., 2014). In this context,
genetic deletion of CB1 in glutamatergic or GABAergic neurons of
EAE mice provided a conclusive demonstration that distinct
subsets of these receptors are involved in both modulation of
TNF-a-mediated postsynaptic exacerbation of glutamate currents,
and IL-1b-dependent presynaptic increase of glutamate release
induced in GABAergic projection neurons of the striatum (Musella
et al., 2014). Moreover, IL-1b inhibits GABA synapses, and this
effect further contributes to the excitotoxic damage of neurons
during EAE and MS (Mandolesi et al., 2015). In keeping with its
homeostatic role in neuroinﬂammatory disorders, CB1 on GABAer-
gic nerve terminals is selectively downregulated in the striatum of
EAE mice, so that increased eCB levels in these animals only reduce
excitatory transmission without affecting GABA signalling (Cen-
tonze et al., 2007a,b).
On the other hand, AEA can also bind to the transient receptor
potential vanilloid type-1 (TRPV1) ion channel (Zygmunt et al.,
1999), whose activation may negatively impact on neuronal
survival. TRPV1 also modulates the synaptic effects of TNF-a and of
IL-1b, hindering the synaptic deﬁcits exerted by TNF-a in the peak
phase of EAE and, in the chronic stages, enhancing IL-1b-induced
GABAergic defects (Musumeci et al., 2011). These data suggest that
the aversive or protective effects of TRPV1 on MS neurons are
strictly dependent on the inﬂammatory milieu. Although it is still
unclear which is the main cell type responding to central
inﬂammation via eCB release, neural precursor cells appear good
candidates, because they respond to inﬂammatory stimuli and to
sensitized TRPV1 receptors (Stock et al., 2014), and limit
inﬂammatory synaptic damage through AEA release (Butti et al.,
2012). The mechanisms by which these elements of the eCB system
modulate the presynaptic and postsynaptic perturbations induced
by inﬂammation are depicted in Fig. 4.
Taken together, preclinical data strongly suggest that modula-
tion of the eCB system is actively involved not only in the
management of symptoms but also in neuroprotection andPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dsuppression of inﬂammation. These observations are generating
considerable enthusiasm for bringing cannabinoid/eCB-based
medicines into clinical practice for the treatment of both
relapsing-remitting and progressive forms of MS. A further support
to this perspective comes also from the experimental demonstra-
tion that plant-derived cannabinoids limit inﬂammation-induced
neurodegeneration that drives progressive disability during EAE
(Pryce et al., 2015). For example, in two different murine models of
MS, Sativex slowed down MS progression by improving motor
activity, reducing CNS inﬁltrates and microglial activity, together
with promoting myelin repair (Feliú et al., 2015) and improving the
neurological deﬁcits and cell inﬁltrates within the CNS. This effect
was attributed to THC activation of CB1 receptors and not to CBD in
the EAE model (Moreno-Martet et al., 2015), while in the viral
model both THC and CBD were effective. However CBD, the
cannabinoid that is devoid of psychoactive activity and potentially
safe, has also been investigated as an effective alternative for
alleviating neuroinﬂammation and neurodegeneration (Maccar-
rone et al., 2017). CBD ameliorates EAE clinical symptoms and
reduces axonal damage and inﬂammation, as well as microglial
activation, T-lymphocyte recruitment in the spinal cord (Kozela
et al., 2011) and protection of oligodendrocyte progenitor cells
from neuroinﬂammation-induced apoptosis (Mecha et al., 2012).
These anti-inﬂammatory and neuroprotective actions of CBD are
long-lasting (Mecha et al., 2013), counteract neuronal apoptosis
(Giacoppo et al., 2015) and antagonistically interact with PEA
(another non-psychotropic compound) in protecting against
neurodegeneration and neuroinﬂammation (Rahimi et al., 2015).
This is probably due to a cross-talk between the CBD-induced PI3K/
Akt/mTOR pathway and upregulation of the PEA-binding PPARg
(Giacoppo et al., 2017). The most recognized effects of CBD are the
immunoregulatory ones, namely (i) suppressing proinﬂammatory
Th17 responses, (ii) promoting T cell exhaustion/tolerance, (iii)
enhancing IFN-dependent anti-proliferative programs, (iv) ham-
pering antigen presentation, and (v) inducing antioxidant milieu
that resolves inﬂammation (Kozela et al., 2016).
3.2. eCB signaling from preclinical models of MS to clinical
applications
A great amount of preclinical studies have convincingly
demonstrated neuroprotective, neuromodulatory and immuno-
modulatory role of cannabinoids and eCBs, and their ability to
alleviate symptoms and behavioural abnormalities in models of
neurological diseases (Baker et al., 2001; Pryce et al., 2003;
Centonze et al., 2007b; Chiurchiù, 2014; Chiurchiù et al., 2015a).
Various cannabinoid preparations have also been examined in
clinical studies to assess their efﬁcacy in humans. Thus, distinct
pharmaceutical preparations of cannabinoid agents have been or
are being tested in numerous human diseases and, besides the
aforementioned Sativex1 and CBD, these include natural cannabi-
noid or phytocannabinoids such as Bedrocan1 (19% THC, <1% CBD
from Cannabis sativa), Bedrobinol1 (12% THC, <1% CBD from
Cannabis sativa), Bediol1 (6% THC, 7,5% CBD from Cannabis sativa),
Bedica1 (14% THC, <1% CBD from Cannabis indica), Bedrolite1 (19%
THC, <1% CBD from Cannabis sativa), and Bedropuur1 (20–24%
THC, <1% CBD from Cannabis indica). In addition, also synthetic
cannabinoids, such as Dronabinol (Marinol1, a synthetic THC),
Nabilone (Cesamet1, a THC analog), and Levonantradol (a
synthetic analog of Dronabinol) have been used in humans. These
preparations can be taken per os mixed with food or made into tea,
or by sublingual or topical administration, or they can be smoked
or inhaled. However, these formulations are extremely heteroge-
neous in nature, making the results of the clinical studies
incomparable, and contributing to inconclusive evidence of
cannabinoid efﬁcacy in most clinical studies.id system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Fig. 4. Overall scheme of the presynaptic and postsynaptic perturbations mediated by proinﬂammatory cytokines and modulated by eCB system in EAE. IL-1b increases
glutamate release at presynaptic terminals and TNF induces AMPA receptor upregulation, resulting in enhanced glutamate transmission. CB1 contrasts the effects of IL-1b by
reducing the frequency of spontaneous glutamate-mediated synaptic currents on presynaptic terminals, conversely TRPV1 is permissive for IL-1b synaptic effects on
glutamate transmission. At the postsynaptic site, both CB1 and TRPV1 restrain TNF-mediated potentiation on postsynaptic AMPA receptor. Moreover, IL-1b promotes the
inhibition of CB1 function on GABAergic synapses, thus mitigating the reduction of GABA release. Moreover, IL-1b reduces postsynaptic GABAA receptor function by
promoting the decrease of GABA signaling. Finally, TRPV1 channels are permissive for IL-1b synaptic effects at both pre- and postsynaptic sites.
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efﬁcacy results of randomized clinical trials that compared
cannabinoids to placebo in three neurological disorders (MS,
epilepsy and movement disorders) published in the preceding 50
years (1948–2013 interval) (Koppel et al., 2014; Gloss and Vickrey,
2014). According to the method of the American Academy of
Neurology, quality evidence was rated as A (established with
strong evidence as effective, ineffective or harmful, supported by 2
Class I studies), B (established with moderate evidence as probably
effective, ineffective or harmful, supported by 1 Class I study), C
(established with weak evidence as possibly effective, ineffective
or harmful, supported by 1 Class II study), or U (insufﬁcient,
inadequate or conﬂicting data to make a determination). This
rather stringent analysis approach showed that efﬁcacy evidence
of the published studies is generally weak, in clinical conditions
other than MS-associated spasticity and neuropathic pain, and in
the case of preparations other than nabiximols (Koppel et al., 2014;
Maccarrone et al., 2017).
As reported in another recent and rigorous systematic review
and meta-analysis considering ten diverse clinical conditions,
cannabis-based medications were generally found to be effective
for the majority of the explored clinical outcomes (Whiting et al.,
2015). In the presented meta-analysis, only randomized trials
comparing cannabinoid preparations with no treatment, placebo
or standard care were considered, and non-randomized clinical
studies were considered only if at least 25 patients were included
(Whiting et al., 2015). Depression was the only clinical conditions
in which placebo was reported to be more effective than
nabiximols in three clinical studies, while cannabis-based med-
ications were conﬁrmed to be more effective than placebo on thePlease cite this article in press as: V. Chiurchiù, et al., The endocannabinoi
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dprimary outcomes of the selected studies in conditions like
spasticity due to multiple sclerosis or paraplegia, neuropathic pain,
cancer pain, but also anorexia secondary to HIV/AIDS, nausea and
vomiting due to chemotherapy, sleep disorders, anxiety, psychosis
and Tourette syndrome (Whiting et al., 2015).
Despite the limitations and poor quality of most clinical trials,
the positive results of some rigorously conducted clinical studies
and the acceptable side effects of most cannabinoid preparations
(the most common adverse effects are dizziness, drowsiness and
disorientation), led to the approval of Nabiximol as the only
cannabis-based drug available in Canada, New Zealand and several
European and Asian countries (but not yet in the U.S.A.) for the
control of spasticity and neuropathic pain associated with MS.
There are few clinical trials assessing efﬁcacy and pharmaco-
logical modulation of cannabinoids and eCBs as disease modifying
treatments (Table 3). The CAMS study (Zajicek et al., 2003, 2005;
Katona et al., 2005), failed to report any effect of cannabinoids on
serum levels of proinﬂammatory cytokines and on T cell activation.
The CUPID study (Zajicek et al., 2013) showed that Marinol1,
(approved as an antiemetic and anorexic drug) has no overall effect
on the progression of MS even in a long-term follow-up study (Ball
et al., 2015). Furthermore, a two-fold cross over study measuring
immune function in progressive MS patients revealed a pro-
inﬂammatory role of Dronabinol (Killestein et al., 2003). Although
MS progression and associated grey matter damage are both
accelerated in human subjects carrying a genetic variant of CB1
with reduced membrane expression (Ramil et al., 2010; Rossi et al.,
2011a, 2013), clinical trials designed to investigate the neuro-
protective effect of cannabinoid-based drugs did not show any
impact on modulation of disease progression. In summary, thed system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Table 3
Outcomes and results of cannabinoid-based clinical trials in MS.
Trial name (source) Study design Disease No. Formulation Duration Main/other clinical
outcomes
Results
CAMS study Zajicek
et al. (2003)
MC, PC, randomized RR-MS,
P-MS
630 Oral THC, THC/
CBD, Placebo
15 weeks Change in overall
spasticity scores
No signiﬁcant improvement of
spasticity
Admission for relapses Reduction of admissions for relapses in
the treated groups
Killestein et al. (2003) Two-fold crossover P-MS 16 Oral THC/
Cannabis sativa
extract
4
weeks + 4
weeks
Immunomodulation Increase of TNF-a in LPS-stimulated
whole blood in the group treated with
Cannabis sativa and increased IL-12p40
in patients with high adverse events
score
CAMS study follow up
Zajicek et al. (2005)
MC, PC, randomized RR-MS,
P-MS
502 Oral THC, THC/
CBD, Placebo
12
months
Efﬁcacy and long term
safety in MS
Small effect on muscle spasticity and
disability, measured by EDSS and RMI
Admission for relapses No reduction of admission for relapses
Katona et al. (2005) MC, PC, randomized P-MS 100 Oral THC, THC/
CBD, Placebo
13 weeks Immunomodulation No evidence for inﬂuence on serum
levels of IFN-g, IL-10, IL-12 and
C-reactive protein
CUPID study Zajicek
et al. (2013)
MC, DB, PC, randomised,
parallel-group trial
P-MS 498 Dronabinol/
Placebo
3 years Efﬁcacy of treatment in
slowing MS progression
No overall effect on the progression
New or enlarging T2
lesions or new T1 lesions
No difference
Brain atrophy No difference
Abbreviations: No., number of subjects; MC, multicentric; PC, placebo-controlled; DB, double-blind; EDSS, expanded disability status scale; P, progressive; RMI, rivermead
mobility index; RR, relapsing-remitting.
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cannabinoids are able to control spasticity in MS patients, but
do not confer neuroprotection in progressive MS. Curiously,
notwithstanding the potent anti-inﬂammatory and neuroprotec-
tive effects of CBD and its low psychoactivity, all clinical trials for
MS entail formulations with mixtures of THC and CBD but no
formulation with only CBD. GW pharmaceuticals is seeking
approval from the FDA to make Epidiolex (an oral formulation
of 99% pure plant-derived CBD) commercially available for the
treatment of several forms of epilepsies and epilepsy-associated
rare syndromes; however, no clinical trials with this drug have
been run or are being planned for MS.
As for drugs speciﬁcally targeting CB receptors, after the
withdrawal of Rimonabant (a CB1 inverse agonist) for its
potentially serious side effects, alternative strategies would be
either to develop novel CB1 ligands that are peripherally restricted
(i.e., unable to cross the blood-brain barrier) and/or exhibit neutral
antagonism, or to eventually bring CB2 agonists into clinical
practice. All these strategies are subject of intense research. Several
clinical trials have been reported or are ongoing with MAGL and
FAAH inhibitors (see for a recent review Chicca et al., 2015). For
example, the irreversible MAGL inhibitor ABX-1431 has success-
fully completed phase 1a clinical trials and is now being evaluated
for Tourette syndrome (phase 1b) and is scheduled for a phase 2
study in MS patients. The FAAH inhibitor PF-04457845 exhibited
also a favourable safety proﬁle in phase 1 and 2 clinical trials, but
was ineffective in treating pain in osteoarthritis patients (Ahn
et al., 2011; Li et al., 2012). The compound is currently being
evaluated for the treatment of Tourette syndrome, fear responses
and cannabis withdrawal. The development of FAAH inhibitors
suffered a major setback with the phase 1 clinical trial of BIA 10-
2474, which led to the death of one volunteer and mild-to-severe
neurological symptoms in four others (Kerbrat et al., 2016).
Recently, it was shown that BIA 10-2474 is a promiscuous drug that
inhibits multiple lipases, including Neuropathy Target Esterase,
that are not targeted by the highly selective and the clinically safe
FAAH inhibitor PF-04457845 (van Esbroeck et al., 2017). BIA 10-
2474, but not PF-04457845, produced substantial alterations in
lipid networks in human cortical neurons, thereby suggesting that
BIA 10-2474 has the potential to dysregulate metabolic pathways
in the nervous system (van Esbroeck et al., 2017). It is, therefore,
highly unlikely that inhibition of FAAH caused the adverse effectsPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://din the healthy volunteers. None of these drugs, nor any other
selective inhibitor of the degradation of the other major eCB, 2-AG,
has so far been used in clinical practice in relapsing or progressive
forms of MS.
4. eCB signaling as a potential therapy for other
neurodegenerative diseases with an inﬂammatory component
Despite the aetiology (where known) and the pathogenesis of
other neuroinﬂammatory diseases such as Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD) and
amyotrophic lateral sclerosis (ALS) are divergent and heteroge-
neous, it can be stated that neuroinﬂammation is a common
hallmarks for all of them. Of note, all these disorders are
characterized by a progressive loss of structure or function of
neurons found at speciﬁc circuitries and brain areas. They all show
subcellular histopathological similarities that include atypical
protein deposits and cell death. In addition, the term neuro-
inﬂammation classically involves inﬁltration of peripheral im-
mune cells within the CNS, but its current use has expanded to
include those neurodegenerative diseases where, although leuko-
cyte recruitment is not a critical feature, cellular and molecular
signs of inﬂammation (i.e., expression of cytokines and other
inﬂammatory mediators as well as glial activation) not only are
present but are likely to contribute to disease pathogenesis and
progression.
The role of the eCB system in these disorders has been
extensively reviewed in recent papers (Chiurchiù et al., 2015a;
Centonze et al., 2007b; Di Marzo et al., 2015; Fernández-Ruiz et al.,
2015). Similarly to MS, perturbations of different components of
the eCB system have been reported, being CB1, CB2 and eCB levels
either increased or decreased in different brain areas (especially for
CB1), speciﬁc cell types or disease stages (Centonze et al., 2007a,b;
Westlake et al., 1994; Benito et al., 2003; Lastres-Becker et al.,
2003; Witting et al., 2004; Horne et al., 2013; Ramirez et al., 2005;
van der Stelt et al., 2006; Yiangou et al., 2006; Battista et al., 2007;
Zhao et al., 2008; Pisani et al., 2011; Jung et al., 2012; Bari et al.,
2013; Altamura et al., 2015) (Table 4). For instance, stimulation of
CB1 leads to a generally reduced glutamate-induced excitotoxicity
and improved neuronal viability (van der Stelt et al., 2001;
Marsicano et al., 2003; Bilsland, 2006), whereas an increase in the
expression of CB2 is usually associated with activated microgliaid system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Table 4
Alterations of distinct elements of the eCB system in neuroinﬂammatory diseases other than MS (pertinent references are in parenthesis).
ECS element AD PD HD ALS
AEA #AEA in brain (Jung et al., 2012) "AEA in basal ganglia, CSF
and blood (Pisani et al.,
2011; Di Filippo et al.,
2008)
#AEA in basal ganglia (Lastres-Becker
et al., 2003)
"AEA in spinal cord
(Witting et al., 2004)
"AEA in blood (Battista et al., 2007)
NAPE-PLD/
FAAH
"FAAH in astrocytes and
microglia (Benito et al., 2003)
– #NAPE-PLD and FAAH in striatum (Bari
et al., 2013)
–
#FAAH in blood (Battista et al., 2007)
2-AG "in brain (van der Stelt et al.,
2006; Altamura et al., 2015)
"in basal ganglia (Pisani
et al., 2011)
#in basal ganglia (Lastres-Becker et al.,
2003)
"in spinal cord (Witting
et al., 2004)
DAGL/MAGL "DAGL in brain (van der Stelt
et al., 2006; Altamura et al.,
2015)
– #DAGL in striatum (Bari et al.115) –
#MAGL in cortex (Bari et al., 2013)
CB1 #in hippocampus and frontal
cortex (Westlake et al., 1994;
Ramirez et al., 2005)
"in basal ganglia (Pisani
et al., 2011)
#in neuropeptide Y interneurons
(Horne et al., 2013)
"in spinal cord and motor
neurons (Witting et al.,
2004; Zhao et al., 2008)
 !in astrocytes and microglia
(Benito et al., 2004)
#in GABAergic neurons (Centonze
et al.120)
CB2 "in astrocytes and microglia
(Benito et al., 2003)
– – in spinal cord and
microglia (Witting et al.,
2004; Yiangou et al.,
2006)
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal ﬂuid; HD, Huntington’s disease; PD, Parkinson’s disease. ", increase; #, decrease;  !,
unchanged.
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et al., 2005) and its activation induces anti-inﬂammatory and
neuroprotective effects in AD (van der Stelt et al., 2006; Martín-
Moreno et al., 2012), PD (Concannon et al., 2015), HD (Palazuelos
et al., 2009) and ALS (Moreno-Martet et al., 2014). Moreover, the
levels of eCBs, in particular of 2-AG, are mostly increased upon
neuronal injury (Panikashvili et al., 2001), and overall they appear
to exert neuroprotective effects. Accordingly, pharmacological
and/or genetic inhibition of eCB degrading enzymes led to
decreased neuroinﬂammation and neurodegeneration in various
animal models of these neuroinﬂammatory diseases (Baker et al.,
2001; Mestre et al., 2005; Ortega-Gutiérrez et al., 2005;
Eljaschewitsch et al., 2006; de Lago et al., 2004; Webb et al.,
2008; Pryce et al., 2013; Amor et al., 2005; Bernal-Chico et al., 2015;
Hernández-Torres et al., 2014; Brindisi et al., 2016; Chen et al.,
2012). Recent studies indicate that inhibition of biosynthesis or
degradation of 2-AG may also exert anti-neuroinﬂammatory
effects through a mechanism independent of CB1 and CB2.
Preventing 2-AG degradation through selective MAGL inhibitors
in mouse brain: i) abolished formation of pro-inﬂammatory
prostaglandins that promote neuroinﬂammation (Nomura et al.,
2011), ii) reduced TNF-a and IL-1b release, iii) suppressed
microglial and astrocyte activation, and iv) promoted neuro-
protection independently of CB receptors in different animal
models of AD and PD (Chen et al., 2012; Nomura et al., 2011).
Conversely inhibition of 2-AG biosynthesis through DAGL reduced
lipopolysaccharide-stimulated pro-inﬂammatory cytokines (Oga-
sawara et al., 2016). Although these preclinical results seem
promising, very few clinical trials with eCB-based drugs have been
undertaken in patients affected by these neuroinﬂammatory
diseases, exclusively entailing the use of Dronabinol or Nabiximol.
The effects of the eCB system in these diseases are summarized in
Fig. 5.
4.1. Alzheimer’s disease
AD is the most common form of dementia in older adults. It
usually starts slowly and irreversibly worsens over time, leading to
a progressive decline in cognitive function and memory loss,
caused by the formation of amyloid plaques and neuroﬁbrillaryPlease cite this article in press as: V. Chiurchiù, et al., The endocannabinoi
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dtangles that cause neuronal death. Thus, neuritic plaques, ﬁbrillary
tangles, neuronal loss, damaged synaptic connections, and reactive
gliosis are the histopathological hallmarks of AD. Amyloid plaques
are made of aggregates of b-amyloid (Ab), and other protein
aggregates (like hyperphosphorylated Tau, ubiquitin, and prese-
nilins 1 and 2). Aggregates of hyperphosphorylated Tau protein,
instead, cause the formation of neuroﬁbrillary tangles (Gosselet
et al., 2013). Activated microglia and astrocytes are critical for
neuritic plaques formation and for the onset of an inﬂammatory
response during AD, likely contributing to the disease progression,
but also to Ab removal. Although a signiﬁcant loss of CB1 receptors
has been reported in most brain regions involved in AD, possibly
due to neuronal loss, CB2 receptors are increased mainly in
activated glial cells, and are often associated to an overexpression
of FAAH in the same cells suggesting a key role for eCB signaling in
the modulation of inﬂammation (Cassano et al., 2017). These
ﬁndings led to a plethora of preclinical studies in several
experimental models of AD, aimed at investigating the effects of
speciﬁc cannabis extracts or selective CB1/CB2 agonists and
inhibitors of eCB metabolic enzymes. THC inhibited the aggrega-
tion of Ab induced by acetylcholine esterase (Eubanks et al., 2006),
whereas CBD reduced the in vivo production of glial proinﬂam-
matory molecules in the hippocampus following Ab-induced
neuroinﬂammation (Esposito et al., 2007). In independent studies,
CB1 agonists prevented Ab-induced microglial activation in AD
patients (Ramirez et al., 2005) and amnesia in AD mice (Mazzola
et al., 2003). Instead CB2 activation ameliorated cognitive impair-
ments by suppressing microglia inﬂammatory responses (Ramirez
et al., 2012; Cassano et al., 2017). In vivo administration of the AMT
inhibitor VDM11 or of the MAGL inhibitor JZL184, that increased
the extracellular levels of endogenous AEA and 2-AG respectively,
was beneﬁcial against neurotoxicity by signiﬁcantly reversing
hippocampus damage, decreasing neuroinﬂammation and neuro-
degeneration and improving long-term synaptic plasticity and
memory (van der Stelt et al., 2006; Chen et al., 2012). In addition,
perturbation of MAGL activity has been investigated in animal
models of AD, such as 5XFAD and PS1/APP+ mice (Piro et al., 2012).
Genetic and pharmacological inactivation of MAGL suppressed
proinﬂammatory responses and amyloidosis in a PS1/APP+ AD
mice (Piro et al., 2012). Moreover, in 5XFAD AD mice, inhibition ofd system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
Fig. 5. Schematic representation of the main effects of distinct members of the eCB system in neuroinﬂammatory diseases other than MS. AD, Alzheimer’s disease; ALS,
amyotrophic lateral sclerosis; eCB, endocannabinoid; HD, Huntington’s disease; PD, Parkinson’s disease.
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and improves cognitive function (Chen et al., 2012)
Although the amount of literature on the role of eCB signaling in
AD is impressive, a few case report studies and clinical trials are
available for this disorder, and focus essentially on either
Dronabinol or Nabilone. Although these studies showed a
decreased severity of disturbed behavior and night-time agitation
upon treatment (Volicer et al., 1997; Walther et al., 2006), they
included a low number of patients and none of them evaluated
cognitive or neurodegenerative markers. The ﬁrst randomized,
double-blind, placebo-controlled study conducted on a bigger
cohort (50 patients), assessing also cognitive functions, reported
that a low-dose of THC did not signiﬁcantly reduce dementia-
related neuropsychiatric symptoms after 21 days of treatment (van
den Elsen et al., 2015). Overall, no actual evidence of cannabinoid
effectiveness in the improvement of behavior and other param-
eters of dementia has been yet reported, and more controlled trials
are needed to assess potential beneﬁts on cognitive functions and
neurodegeneration.
Interestingly, the very recent view that eCBs can also function as
epigenetic modulators by inducing alterations in the transcrip-
tional activity of key genes involved in various neurotransmitter
systems (D’Addario et al., 2013), and the evidence that FAAH is
epigenetically regulated in AD patients (D’Addario et al., 2012), has
opened a novel avenue to the possible design of speciﬁc epigenetic
drugs targeting elements of the eCB system.
4.2. Parkinson’s disease
PD is the second commonest neurodegenerative disorder of the
CNS. It is characterized by motor and non-motor symptoms,
including tremor, bradykinesia, muscular stiffness or rigidity and
loss of postural balance as well as constipation and depression. The
underlying pathogenesis is determined by degeneration of
dopamine-producing neurons of substantia nigra, leading to an
impaired dopaminergic neurotransmission in the basal gangliaPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://d(Schapira and Tolosa, 2010). Several mechanisms seem to take part
in the selective degeneration of dopaminergic neurons, including
oxidative stress, mitochondrial dysfunction, excitotoxicity and also
neuroinﬂammation. An important role of the immune system in
the pathogenesis of PD is recent and it seems to involve either
inﬂammation or autoimmunity, due to the identiﬁcation of several
autoantibodies directed towards PD-associated antigens (De
Virgilio et al., 2016). Additionally, microglial activation at neuro-
degeneration sites follows nigral cell death in PD and is critical for
initiation and/or progression of the neurodegenerative process
through the production of a variety of inﬂammatory mediators,
such as cytokines, glutamate and reactive oxygen species (De
Virgilio et al., 2016). These observations led to the hypothesis that
immune activation may be the cause, rather than a consequence, of
the observed neuronal loss. Since CB1 activity is increased in the
basal ganglia and it affects the release of neurotransmitters and the
activity of motoneurons, agonism of this receptor has proven to be
a useful therapeutic strategy for PD. Indeed, CB1 agonists exerted a
protective effect on nigrostriatal dopamine neurons and on
microglial activation in mouse models of PD (Price et al., 2009)
and to attenuate the 6-hydroxydopamine-induced hypokinesia
(Gonzalez et al., 2006). Furthermore, THC or CBD exerted
neuroprotective effects by signiﬁcantly preventing the loss of
nigral dopaminergic neurons and by reducing the denervation of
the ipsilateral striatum (Lastres-Becker et al., 2005). Furthermore,
since eCBs become overactive and generally increase following
dopaminergic neurons denervation, their anti-inﬂammatory
effects might explain their protective role in PD, likely impacting
on the activity of glial cells via CB2 receptors on neurons. Nomura
et al. used a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model for PD, where JZL184 provided neuroprotective
effects, however, these effects remained unchanged by CB receptor
antagonists and were recapitulated by COX inhibition (Nomura
et al., 2011). This indicated that the neuroprotective effects were
not mediated via the CB receptors, but were rather due to
reductions in AA and proinﬂammatory prostaglandins. Mounseyid system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
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Several recent reports have highlighted the critical role of CB2 in
preventing glial-derived neurotoxic mediator production, BBB
leakage and inﬁltration of peripheral leukocytes. Moreover, CB2
protects neurons from oxidative stress-induced dopaminergic
neurodegeneration in several experimental models of PD (Chung
et al., 2016; Javed et al., 2016), suggesting that selectively targeting
this receptor could be indicated for novel clinical approaches. The
ﬁrst clinical studies conducted on PD reported reduction of
levodopa-induced dyskinesia by Nabilone (Sieradzan et al., 2001),
or by cannabis extract (Carroll et al., 2004). Yet, they failed to
demonstrate efﬁcacy in treating dyskinetic patients, probably due
to methodological differences such as small cohort size and the
difﬁcult detection of small changes in dyskinesia. However, current
clinical trials focused their attention to CBD instead of THC, due to
its preliminary beneﬁcial effects for the treatment of psychosis
(Zuardi et al., 2009). On this basis, a recently concluded clinical trial
aimed at exploring the effects of different doses of CBD on PD failed
to document any signiﬁcant difference in motor symptoms with
possible neuroprotective effects (Chagas et al., 2014). A clinical trial
assessing the effects of cannabis on PD-associated tremors has just
been completed, and results should be available soon (Clinical-
Trials.gov Identiﬁer: NCT02028858). The evidence that MAGL-
knockout animals show neuroprotection in a PD model (Nomura
et al., 2011), and that FAAH inhibition decreases abnormal cortical
glutamatergic drive (Gubellini et al., 2002) and reverses motor
symptoms in PD experimental models (Celorrio et al., 2016),
suggest that modulating the endogenous tone of eCBs could be of
therapeutic value via multiple mechanisms of action.
4.3. Huntington’s disease
HD is an autosomal dominant disorder that causes uncontrolled
movements, emotional problems and cognitive loss due to a
mutation in the huntingtin gene, determining an aberrant
aggregation of huntingtin protein, ultimately leading to cytotoxic
effects (Zuccato et al., 2010; Ross and Tabrizi, 2011). Early damage
is mostly evident in the striatum, but as the disease progresses
other areas of the brain are even more affected, like cerebral cortex,
substantia nigra, hippocampus, Purkinje cells of the cerebellum
and some parts of hypothalamus and thalamus. HD also causes an
abnormal increase of astrocytes and microglia activation. Indeed,
aberrant expression of huntingtin solely in microglia is sufﬁcient to
induce their priming and activation of a proinﬂammatory
phenotype (Crotti and Glass, 2015). Also in HD an altered
expression of several elements of the eCB system has been
documented (Table 4). Furthermore, loss of CB1 in neuropeptide Y
interneurons seems to contribute to the impairment of basal
ganglia functions linked to HD (Horne et al., 2013). Down
regulation of CB1 in GABAergic neurons is likely to be a
compensatory mechanism in HD to counteract excitotoxic neuro-
nal damage (Centonze et al., 2005), whereas CB1 receptors located
on glutamatergic terminals seem to be indispensable players in the
neuroprotective activity of (endo)cannabinoids (Chiarlone et al.,
2014). Loss of CB receptors has been recently corroborated by
positron emission tomography in HD patients, suggesting that it
could be among the potential biomarkers able to track HD
pathology (Wilson et al., 2017). In addition, CB2 receptors,
especially located in microglial cells, are pivotal in attenuating
microglial activation and preventing neurodegeneration (Palazue-
los et al., 2009). In analogy with AD and PD, both similarly
characterized by generalized motor and/or cognitive dysfunctions,
cannabinoids were tested in pre-clinical models of HD, and also in
the treatment of symptoms of HD patients. Again, in a mouse
model of HD, CB1/CB2 agonists have been found to exert neuro-
protection (Sagredo et al., 2012), and THC to attenuate deﬁcits inPlease cite this article in press as: V. Chiurchiù, et al., The endocannabinoi
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://dmotor coordination and protein aggregation (Blázquez et al., 2011).
Furthermore, oral CBD has been used in the ﬁrst clinical trial for HD
patients, but its efﬁcacy was not much different from placebo
(Consroe et al., 1991). Lack of relieve of HD symptoms was also
reported for Nabilone (Curtis et al., 2009). A recently concluded
pilot study with Nabiximol proved its safety, tolerability and
absence of severe adverse events, but no signiﬁcant beneﬁts on
motor, cognitive, behavioral and functional scores (López-Sendón
Moreno et al., 2016). If and how cannabinoids could be there-
pautically used as drugs for the management of this disorder has to
be further investigated. At any rate the presence of a neuro-
inﬂammatory component in HD should prompt the study of eCB
signalling to potentially modulate microglial immune activation.
4.4. Amyotrophic lateral sclerosis
ALS is the most common degenerative disease of the motor
neuron system of the spinal cord and brain stem, leading to a
progressive atrophy of several voluntary muscles, thus impacting
on key movements like chewing, swallowing, talking and even
breathing, eventually causing death. Of note, 90–95% of all cases of
ALS are sporadic but their aetiology is still unclear. On the contrary,
a lot more is kown for familiar ALS (5–10%), whereby more than 20
genetic mutations have been associated with ALS. Mutations of Cu/
Zn superoxide dismutase (SOD1) makes up to approximately 20%
of all familial cases (Kiernan et al., 2011), but the pathogenesis of
motoneuron degeneration remains unclear. Glutamate excitotox-
icity, protein aggregation, mitochondrial dysfunction and oxidative
stress, proteosomal dysfunction, axonal transport deﬁcit, and
cytoskeletal abnormalities seem all to be involved. Currently, ALS is
recognized as a multifactorial disorder, whereby single genes or
multiple determinants could cause it, including immunologic
disturbances. In ALS misfolded protein aggregation and neuro-
inﬂammation also occur and are two hallmarks of this disease
(Swinnen and Robberecht, 2014). Neuroinﬂammation is caused by
an excessive microglial activation, in terms of the modulation of
phagogytosis and inﬂammatory processes as well as regarding the
cross-talk between neuronal and glial cells, that ultimately lead to
motor neuron degeneration (Rodríguez and Mahy, 2016). Some of
these pathogenic mechanisms are associated with SOD1 activity,
but are also modulated by the eCB system. This could be the reason
why increasing eCBs and their receptors activity in several ALS
experimental models is neuroprotective (Table 4). Increased AEA
and 2-AG levels during ALS-associated excitotoxic damage are
likely to play a neuroprotective role, and thus manipulating the eCB
system may be therapeutically exploited for the treatment of ALS.
Although evidence on the effect of cannabinoids in ALS is still poor,
these compounds are likely to exert powerful antioxidative, anti-
inﬂammatory and neuroprotective effects and cause analgesia,
muscle relaxation, prolonged neuronal survival and delayed
disease onset and progression in experimental ALS models (Raman
et al., 2004; Kim et al., 2006; Shoemaker et al., 2007; Rossi et al.,
2010). Similar effects have been obtained using a Sativex1-like
drug, namely an equimolecular combination of THC- and CBD-
enriched botanical extracts (Moreno-Martet et al., 2014), calling for
human clinical trials (Carter et al., 2010). The only completed trial
conducted in ALS recruited 22 patients that were treated with
orally administered Dronabinol for cramps. Although the trial
failed to prove a subjective improvement of cramp intensity
(Weber et al., 2010), an ongoing phase III trial (CANALS) is assessing
safety and efﬁcacy of Dronabinol on spasticity in motor neuron
diseases including ALS, whereas a recently completed trial on 9 ALS
patients assessed the pharmacokinetics and tolerability of THC and
concluded that because of high interindividual variability in
pharmacokinetics individual posology of THC is required for
potential therapeutic use (Joerger et al., 2012). Thus, the possibilityd system and its therapeutic exploitation in multiple sclerosis: Clues
oi.org/10.1016/j.pneurobio.2017.10.007
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remains a major challenge for future clinical research. In view of
recent evidence on the role of neuroinﬂammation and microglia
involvement in ALS, along with increased CB2 expression in
activated microglia from spinal cord of human ALS patients
(Yiangou et al., 2006), future investigations are warranted on
strategies that selectively activate the latter receptor subtype.
5. Conclusions and future directions
Preclinical and clinical studies have highlighted the complexity
of cannabinoids, eCBs, their receptors and metabolizing enzymes,
which form an intricate network with multiple biological actions
within the CNS and at the periphery. Remarkably, a wealth of
preclinical and clinical data proved that cannabinoid-based
medicines reduce spasticity symptoms in MS and also in other
neurodegenerative diseases, probably through CB1-dependent
modulation of synaptic activity and neurotransmission. Yet,
molecular mechanisms underlying dysregulation of neuronal
circuits in MS are likely different from those of other neuro-
inﬂammatory diseases, so far leading to commercial approval of
these medicines only for MS.
Furthermore, cannabinoid-based drugs are ineffective at
halting neurodegeneration and disease progression for any of
these neuroinﬂammatory disorders in patients. This lack of efﬁcacy
remains unclear, and could be related to: i) dosage and
administration uncertainties, ii) illness progression stage of
patients, and iii) inability to modulate CB2-dependent anti-
inﬂammatory and neuroprotective actions. These studies are also
affected by the use of subjective scales as end-points, and by a
strong placebo effect (Di Marzo et al., 2015). Therefore, it is deemed
necessary to start large randomized placebo-controlled trials with
objective end-points, in order to obtain conclusive results on the
beneﬁcial effects of cannabinoids and eCB-based drugs.
Additionally, patients are usually allowed to self-titrate the dose
of the cannabinoid-based medicine to reduce the adverse side
effects associated to CB1 activation. Could it be that CB1 is lost with
disease progression? If so, cannabinoid-based therapy should start
earlier. Or is perhaps the dose too low to stimulate CB2? Selective
CB2 agonists would, therefore, be ideal drug candidates to be tested
in both early and progressive phases of MS. Alternatively,
enhancement of the endogenous levels of eCBs by inhibiting
FAAH and/or MAGL appears an opportunity to be tested in MS
patients, because it is expected to control spasticity symptoms,
provide neuroprotection and exert anti-inﬂammatory actions.
These options could represent an exciting translational frontier to
obtain drugs to treat inﬂammatory-associated neurodegenerative
diseases targeted towards different elements of the eCB system.
Conceivably, cocktails of eCB-based drugs, or their combination
with conventional therapies, might have more beneﬁcial effects by
acting synergistically. However, one possible obstacle to such a
synergistic approach could be the heterogeneous plasticity of
immune cells, especially those belonging to the innate compart-
ment. Innate immune cells such as macrophages/microglia, on the
one hand, can prevent overactive immune responses and
autoimmunity by promoting a tolerogenic environment and by
secreting neurotrophic growth factors. On the other hand, these
cells can play an immunopathogenic role by inducing and/or
exacerbating pro-inﬂammatory activities (Gandhi et al., 2010). For
instance, similarly to peripheral macrophages, also microglia has
different activation states that go from the classically-activated
and pro-inﬂammatory to the alternatively-activated and resolving
phenotype, and the fact that eCBs seem to be critical for inducing
microglia to acquire the protective state (Mecha et al., 2015)
suggests that eCB signalling could be explored to generate a
reparative environment in neurodegenerative diseases (MechaPlease cite this article in press as: V. Chiurchiù, et al., The endocannabino
for other neuroinﬂammatory diseases, Prog. Neurobiol. (2017), https://det al., 2016). Thus, as the role of resident or inﬁltrated innate
immune cells becomes better deﬁned, it will be possible to design
therapies aimed at driving their plasticity in favour of an anti-
inﬂammatory and neuroprotective activity.
Notably, distinct elements of the eCB system might be useful
biomarkers for diagnostic purposes, and able to predict disease
evolution in MS patients. For instance, AEA levels in cerebrospinal
ﬂuid are strikingly indicative of active phases of MS, even
asymptomatic but nonetheless associated with acute blood brain
barrier disruption and lymphocyte inﬁltration (Centonze et al.,
2007a,b). However, standardized and optimized protocols for the
determination of eCB levels in human biological ﬂuids and biopsies
are required to minimize variability in the determination of their
content.
On a ﬁnal note, MS and other neuroinﬂammatory diseases are
multifactorial, where also environmental factors play an impor-
tant role. In this context, due to the strong interplay between
genes and the environment, an eCB-based “epigenetic therapy”
could provide a new approach, with the aim of designing more
speciﬁc epigenetic drugs devoid of genome-wide or off-target
effects. In this context, physical therapy has gained room as a
novel treatment able to rescue several functions in MS patients
with disability, but also to mitigate the associated neuropatho-
logical alterations (Feinstein and Dalgas, 2014; Feinstein et al.,
2015). The evidence that physical exercise modulates eCB
signalling, for example by increasing eCB levels in the brain
(Ferreira-Vieira et al., 2014; Galdino et al., 2014) and by
sensitizing CB1 at central synapses (De Chiara et al., 2010;
Tantimonaco et al., 2014), suggests that its beneﬁcial effects
might be mediated in part by epigenetic modulation of eCB
signalling (Dubreucq et al., 2013; Chaouloff et al., 2011). One way
to give biochemical ground to these observations would be
ﬁnding the genetically regulated CB1 function in order to predict
clinical response to cannabinoid treatment of spasticity (Coghe
et al., 2015; Leocani et al., 2015), and to improve patient
stratiﬁcation as a tool for personalized rehabilitation of MS
patients with disability.
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